Education
About Us
Working with TipRanks
Follow Us
Helix BioPharma (TSE:HBP)
TSX:HBP
HBP Stock Chart & Stats
C$2.40
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.40
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.65 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$152.76M
Enterprise ValueC$152.61M
Total Cash (Recent Filing)C$498.00K
Total Debt (Recent Filing)C$352.00K
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetVery low debt relative to equity provides durable financial flexibility for a clinical-stage biotech. Modest leverage reduces near-term refinancing risk, preserves optionality to fund trials or seek partners, and lengthens runway versus peers with higher debt burdens.
Improving Cash-burn TrendA measurable reduction in operating cash burn indicates effective cost containment and operational discipline. Sustained improvement can materially extend runway without dilutive financing, making the company better positioned to reach clinical inflection points or attract partners.
Regulatory And Operational ProgressPositive FDA feedback on study design reduces regulatory execution risk, while streamlining operations and targeted financing demonstrate management alignment to preserve capital. These structural actions improve prospects of reaching pivotal clinical milestones more efficiently.
Bears Say
No Revenue; Persistent Net LossesAbsence of product revenue and repeated net losses are durable constraints for a clinical-stage firm: they necessitate continual external funding, limit organic reinvestment capacity, and mean value depends entirely on future trial success and licensing or commercialization events.
Negative Operating & Free Cash FlowSustained negative operating and free cash flow create structural funding risk. Even with improved burn, the company cannot self-fund development, making timelines and strategy contingent on dilutive financings or partner deals that may alter economics or timing of clinical programs.
No Commercial Products; Limited Internal ScaleWith no approved products and no disclosed licensing arrangements, the firm lacks recurring revenue and demonstrated commercialization capability. Combined with a very small employee base, this increases execution risk and dependence on partners for late-stage development and eventual market access.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.65 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$152.76M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Mar 18, 2026 which is in 23 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Dec 12, 2025. The company reported -C$0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.013.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.49%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---